Does Dr. SCOTT DINEHART have financial conflicts of interest?

Dr. SCOTT DINEHART (M.D.) has received a total of $152,452 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $146,309 in personal promotional payouts (consulting, meals, travel) and $6,142 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. SCOTT DINEHART?

According to CMS Open Payments data, Dr. SCOTT DINEHART received funding from GENENTECH USA ($66,565), SUN PHARMACEUTICAL INDUSTRIES ($47,528), and REGENERON PHARMACEUTICALS ($15,436).

Does Dr. SCOTT DINEHART receive research grants or speaking fees?

Dr. SCOTT DINEHART has received $146,309 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $6,142 in clinical research grants.

DR. SCOTT DINEHART

M.D.Real-Time Hydrated

Specialty: Dermatology, MOHS-Micrographic Surgery

Practice Location: LITTLE ROCK, AR 72205

NPI Number: 1922065044

LIFETIME INDUSTRY VALUE

$152,452

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. DINEHART is a verified Dermatology, MOHS-Micrographic Surgery practitioner based in LITTLE ROCK, AR.

Between 2021 and 2025, Dr. DINEHART had an overall industry promotional and research financial footprint of $152,452 as recorded in the federal CMS Open Payments database.

$146,309 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$6,142 was allocated to sponsored clinical trials and medical research activities.

Dr. DINEHART's primary funding source is GENENTECH USA, which accounts for $66,565 (representing 43.7% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

GENENTECH USA

Rank 1

$66,565

43.7%

SUN PHARMACEUTICAL INDUSTRIES

Rank 2

$47,528

31.2%

REGENERON PHARMACEUTICALS

Rank 3

$15,436

10.1%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.